Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Estriol may ease menopause-related cognitive decline
Women reported improvement across 6 cognitive domains during 12 months of estriol-based treatment, while murine models suggested a potential astrocyte-mediated mechanism.
To assess the effects of estriol-based hormone treatment on cognitive symptoms in menopausal women.
Approach:
Study Design: A case series involving 20 menopausal women with a mean age of 53.5 years, treated with oral estriol for 12 months.
Treatment Details: Participants received daily doses of estriol (2 mg, 4 mg, or 8 mg) and progesterone as needed.
Cognitive Assessment: Cognitive symptoms were evaluated at baseline and after 12 months using the Voskuhl Menopause Brain Fog Assessment.
Key Findings:
Statistically significant improvements were observed across all six cognitive domains assessed based on self-reported symptoms.
Subgroup analyses showed improvements regardless of age, education, recent estradiol use, or estriol dose.
Preclinical studies in mice indicated that estriol treatment reduced cognitive deficits and glial activation.
Interpretation:
The study suggests potential cognitive benefits of estriol treatment in menopausal women, but findings should be interpreted with caution due to the study's limitations.
Limitations:
Small sample size of only 20 women.
Lack of randomization and comparison group.
Cognitive changes measured through self-reported symptoms rather than objective testing.
Conclusion:
Further investigation into estriol-based treatment for cognitive symptoms of menopause is warranted.
Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.